IGF2 and colorectal carcinoma: Zanell et al., in an interesting study of CRC samples from “xeno-patients” responsive to cetuximab, showed that a subset of cases (37.5%) in which enhanced EGFR inhibition was unproductive exhibited marked overexpression of IGF2.